
C-MIC Device. Image Credit: Berlin Heals
Berlin Heals has announced the first patient implantation in C-MIC IV, a randomized, double-blind trial of its cardiac microcurrent device. The study plans to enroll 60 patients across six European countries, assigning them equally to active therapy or sham control. All participants will receive an implant, with treatment activation concealed from patients and assessing clinicians.
C-MIC delivers a constant electrical microcurrent intended to improve cardiac function. The study includes symptomatic heart failure of ischemic and non-ischemic origin, with reduced ejection fraction above 20%. Its principal significance is the opportunity to evaluate the therapy under blinded conditions. According to the company, the findings will help inform a planned pivotal IDE trial.
